| 174.34 -2.74 (-1.55%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 241.28  |
1-year : | 268.19 |
| Resists | First : | 206.57 |
Second : | 229.61 |
| Pivot price | 193.62 |
|||
| Supports | First : | 169.3 |
Second : | 140.86 |
| MAs | MA(5) : | 179.42 |
MA(20) : | 198.37 |
| MA(100) : | 222.72 |
MA(250) : | 187.82  |
|
| MACD | MACD : | -9.1 |
Signal : | -6.7 |
| %K %D | K(14,3) : | 7.5 |
D(3) : | 5.3 |
| RSI | RSI(14): 25.8 |
|||
| 52-week | High : | 260.19 | Low : | 117.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXSM ] has closed above bottom band by 11.3%. Bollinger Bands are 70.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 177.67 - 179.38 | 179.38 - 180.41 |
| Low: | 165.73 - 167.93 | 167.93 - 169.26 |
| Close: | 171.77 - 175.42 | 175.42 - 177.62 |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Mon, 05 Oct 2026
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 05 Oct 2026
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
Sun, 04 Oct 2026
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
Fri, 02 Oct 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Wed, 30 Sep 2026
Can Axsome Therapeutics (AXSM) Keep Justifying Its Price On Sales? - Simply Wall Street
Tue, 29 Sep 2026
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.4% on Analyst Downgrade - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 52 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 74.5 (%) |
| Shares Short | 3,210 (K) |
| Shares Short P.Month | 3,020 (K) |
| EPS | -3.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.59 |
| Profit Margin | -24.7 % |
| Operating Margin | -23.5 % |
| Return on Assets (ttm) | -16.4 % |
| Return on Equity (ttm) | -245.2 % |
| Qtrly Rev. Growth | 45.5 % |
| Gross Profit (p.s.) | 13.82 |
| Sales Per Share | 14.82 |
| EBITDA (p.s.) | -3.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -46.62 |
| PEG Ratio | 0 |
| Price to Book value | 109.64 |
| Price to Sales | 11.75 |
| Price to Cash Flow | -128.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|